European Union - English - EMA (European Medicines Agency)

intervet international bv - bluetongue virus vaccine, serotype 8 (inactivated) - inactivated viral vaccines, bluetongue virus, sheep - sheep; cattle - cattle to stimulate active immunity in sheep from 6 weeks of age against bluetongue virus serotype 8 to reduce viraemia sheep to stimulate active immunity in sheep from 1 month of age against bluetongue virus serotype 8 to prevent viraemia,

European Union - English - EMA (European Medicines Agency)

mérial - bluetongue-virus serotype-2 antigen, bluetongue-virus serotype-4 antigen - bluetongue virus, inactivated viral vaccines, immunologicals for ovidae - sheep - active immunisation of sheep to prevent viraemia and to reduce clinical signs caused by bluetongue virus serotypes 2 and 4.

European Union - English - EMA (European Medicines Agency)

merial - bluetongue virus serotype 8 antigen - immunologicals for ovidae, immunologicals for bovidae - sheep; cattle - active immunisation of sheep and cattle to prevent viraemia* and to reduce clinical signs caused by bluetongue virus serotype 8.*(below the level of detection by the validated rt-pcr method at 3.14log10 rna copies/ml, indicating no infectious virus transmission).onset of immunity has been demonstrated 3 weeks after the primary vaccination course.the duration of immunity for cattle and sheep is 1 year after the primary vaccination course.the duration of immunity is not yet fully established in cattle or sheep, although interim results of ongoing studies demonstrate that the duration is at least 6 months after the primary vaccination course in sheep.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - g glycoprotein of hendra virus (sg - protein); thiomersal - misc. vaccines or anti sera - g glycoprotein of hendra virus (sg - protein) vaccine-viral active 100.0 ug; thiomersal mercury other 0.1 mg/ml - immunotherapy

European Union - English - EMA (European Medicines Agency)

seqirus s.r.l.  - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - vaccines - active immunisation against h5 subtype of influenza a virus

European Union - English - EMA (European Medicines Agency)

zoetis belgium sa - inactivated bluetongue virus, serotype 1, strain btv-1/alg2006/01 e1 rp, inactivated bluetongue virus, serotype 8, strain btv-8/bel2006/02 - bluetongue virus, immunologicals, immunologicals for bovidae, cattle, inactivated viral vaccines - cattle - active immunisation of cattle from 3 months of age for the prevention* of viraemia caused by bluetongue virus (btv), serotypes 1 and 8.*(cycling value (ct) ≥ 36 by a validated rt-pcr method, indicating no presence of viral genome).

European Union - English - EMA (European Medicines Agency)

merial - bluetongue-virus serotype-1 antigen - immunologicals - sheep; cattle - active immunisation of sheep and cattle to prevent viraemia and to reduce clinical signs caused by bluetongue virus serotype 1.onset of immunity has been demonstrated three weeks after the primary vaccination course. the duration of immunity for cattle and sheep is one year after the primary vaccination course.

European Union - English - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain a/viet nam/1194/2004 (h5n1) - influenza, human, immunization, disease outbreaks - vaccines, - active immunisation against h5n1 subtype of influenza a virus., this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain., prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.,

European Union - English - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain a/viet nam/1194/2004 (h5n1) - influenza, human - vaccines - active immunisation against h5n1 subtype of influenza a virus.; this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain.; prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.

European Union - English - EMA (European Medicines Agency)

zoetis belgium sa - inactivated bluetongue virus, serotype 1, strain btv-1/alg2006/01, inactivated bluetongue virus, serotype 8, strain btv-8/bel2006/02 - bluetongue virus, sheep, inactivated viral vaccines - sheep - active immunisation of sheep from 1.5 months of age to prevent viraemia caused by bluetongue virus, serotypes 1 and 8.onset of immunity: 21 days after completion of the primary vaccination scheme.duration of immunity: 12 months.